Six startups working on some of the toughest problems in brain health are headed to New Orleans later this month, each hoping to walk away with a share of $100,000 in prizes. The New Orleans BioInnovation Center has named its finalists for the 2026 BioChallenge, a pitch competition set for Thursday, October 29 at the organization's Canal Street headquarters, and this year's lineup is built entirely around neuroscience — companies chasing solutions for ALS, Alzheimer's, hearing disorders and infections that can damage a newborn's developing brain.
The event, detailed by Biz New Orleans, is presented by Dr. Sid O'Bryant and the Institute for Translational Research at UNT Health Fort Worth, with lead sponsorship from Cognito Therapeutics, BioDistrict New Orleans and Answer ALS. According to the outlet's reporting, finalists are traveling from as far as California, Boston and France to pitch judges and look for clinical partners in New Orleans. NOBIC's chief executive, Kris Khalil, said the six companies earned their spots from a deep applicant pool and are well past the idea stage — several, Khalil said, already have a drug or device being tested in human trials.
Devices and Drugs Already in Human Testing
That clinical maturity is visible across the roster. Pathmaker Neurosystems is developing the Myoregulator, a noninvasive device that delivers electrical stimulation through surface electrodes to the spinal cord and peripheral nerves, and it is now in its second clinical trial as a potential ALS treatment, per Biz New Orleans. The device received FDA Breakthrough Device Designation in December 2025, a status that, according to GlobeNewswire, accelerates development and regulatory review for devices treating life-threatening or severely debilitating diseases.
Cenna Biosciences is pursuing a different angle on Alzheimer's disease. The company's lead candidate, 8M2D, is designed to reduce beta-amyloid production rather than clear plaques already built up in the brain, and it received FDA authorization to proceed with its first human clinical trial, according to Biz New Orleans. That mechanism stands apart from most approved monoclonal antibody therapies, which remove accumulated plaques after the fact; as Newswire reported, Cenna's drug instead aims to prevent amyloid formation at its origin.
A Local Spinoff Targets Newborn Brain Health
One finalist has roots much closer to home. Cleaved Diagnostics, a Tulane University spinoff, is building rapid, sensitive and affordable diagnostic tests using CRISPR technology, with its first product aimed at detecting cytomegalovirus, an infection that can affect newborns' brain development and hearing, Biz New Orleans reports. The company's CRISPR-Cas12a platform can detect congenital CMV in under 40 minutes, work that has been backed by a Phase I National Science Foundation STTR grant awarded in August 2025, according to the New Orleans BioInnovation Center. Congenital CMV is a leading cause of hearing loss and neurologic disabilities.
Also on the roster is Moleculera Biosciences, which offers a blood-testing panel designed to help clinicians identify possible immune contributions to psychiatric, behavioral, cognitive or movement symptoms, and the company is expanding its research into other conditions involving inflammation, Biz New Orleans reports. The company’s testing uses antibody measurements in assessing possible infection-related autoimmunity. These conditions, as Moleculera Biosciences notes, can respond to immunomodulatory care rather than traditional psychotropic drugs.
Hearing and Nerve Disorders Round Out the Field
Parley Neurotech, a University of Colorado spinoff, is developing a noninvasive treatment for people who struggle to understand speech in noisy environments and is currently evaluating the approach in a clinical trial, according to Biz New Orleans. The company enrolled its first patient in April for a Phase I/IIa trial combining oral clemastine fumarate with engineered acoustic stimulation, according to the CU Anschutz Newsroom. Difficulty processing speech in noisy settings is an early, modifiable risk factor linked to social isolation and cognitive decline, the university noted.
France-based Nervosave Therapeutics rounds out the group, developing treatments for nerve disorders beginning with Charcot-Marie-Tooth disease, an inherited condition affecting peripheral nerves, and the company is expanding into the United States, Biz New Orleans reports. The Charcot-Marie-Tooth Association discusses localized gene therapy as an approach for the inherited neuropathy.
Why Neuroscience, and Why Now
NOBIC's decision to build this year's BioChallenge entirely around brain health tracks with a global health trend that is hard to ignore. More than 3 billion people — over 1 in 3 globally — lived with a neurological condition in 2021, making neurological disorders the leading cause of ill health and disability worldwide, according to a World Health Organization study. Estimates of the economic costs of brain disorders reach $16 trillion by 2030.
Finalists will present to a panel of judges and compete for $100,000 in total cash prizes, Biz New Orleans reports. Last year's competition was won by JuneBrain Inc., a Baltimore-based company that also took home the crowd favorite award for its AI-powered retinal imaging platform, which remotely detects and monitors neurological conditions. Previous BioChallenge winners have gone on to raise millions of dollars in private investment and federal grant funding, according to the outlet.
A Growing Track Record in Mid-City
The competition continues a partnership between NOBIC and the Institute for Translational Research at UNT Health Fort Worth in recognizing brain-health innovations. Sid O'Bryant said the 2026 BioChallenge participants represent the creativity and potential to turn discoveries into advances that improve lives, according to Biz New Orleans. Founded in 2011, NOBIC has supported more than 250 emerging life-science companies, which have collectively raised over $200 million in private and public capital as of 2025 figures reported by the outlet — part of the broader regional infrastructure Hoodline previously detailed in its coverage of thousands of scientists converging on New Orleans for a major pharmaceutical sciences conference.
The 2026 BioChallenge is open to the public and takes place October 29 at the New Orleans BioInnovation Center, 1441 Canal Street. For a city building out its bioscience footprint, the night offers a direct look at how global neurotech research, from Alzheimer's drug development to newborn infection screening, is finding a landing pad in New Orleans.
